Technical Analysis for ABBV - AbbVie Inc.

Grade Last Price % Change Price Change
grade D 85.93 -1.39% -1.21
ABBV closed down 1.65 percent on Wednesday, September 23, 2020, on approximately normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical ABBV trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish -1.39%
Outside Day Range Expansion -1.39%
Down 3 Days in a Row Weakness -1.39%
Oversold Stochastic Weakness -1.39%
New Downtrend Bearish -3.01%
NR7 Range Contraction -3.01%
Inside Day Range Contraction -3.01%
Oversold Stochastic Weakness -3.01%
Fell Below 200 DMA Bearish -3.55%
Hammer Candlestick Bullish -3.55%
Older End-of-Day Gignals for ABBV ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 6 hours ago
Down 2 % about 6 hours ago
1.5x Volume Pace about 7 hours ago
Down 1% about 7 hours ago
Fell Below Lower Bollinger Band about 7 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has collaboration with Alvine Pharmaceuticals, Inc. to develop a oral treatment for patients with celiac disease. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013.AbbVie Inc. operates independently of Abbott Laboratories.
Chemistry Chemical Compounds Organic Compounds Autoimmune Diseases Pharmaceutical Products Prostate Cancer Chloroarenes Cardiology Cholesterol Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Secondary Hyperparathyroidism Celiac Disease Exocrine Pancreatic Insufficiency Hypothyroidism Lipoproteins Research Based Biopharmaceutical Testosterone Replacement Therapy

Is ABBV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 101.28
52 Week Low 62.55
Average Volume 6,861,098
200-Day Moving Average 89.19
50-Day Moving Average 94.09
20-Day Moving Average 91.27
10-Day Moving Average 89.51
Average True Range 1.92
ADX 26.6
+DI 10.66
-DI 28.57
Chandelier Exit (Long, 3 ATRs ) 90.25
Chandelier Exit (Short, 3 ATRs ) 92.88
Upper Bollinger Band 95.71
Lower Bollinger Band 86.84
Percent B (%b) 0.03
BandWidth 9.72
MACD Line -1.63
MACD Signal Line -1.38
MACD Histogram -0.2541
Fundamentals Value
Market Cap 138.91 Billion
Num Shares 1.59 Billion
EPS 4.07
Price-to-Earnings (P/E) Ratio 21.41
Price-to-Sales 5.35
Price-to-Book 23.76
PEG Ratio 1.00
Dividend 2.56
Dividend Yield 2.94%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 90.37
Resistance 3 (R3) 90.72 89.99 89.83
Resistance 2 (R2) 89.99 89.17 89.82 89.65
Resistance 1 (R1) 88.57 88.66 88.21 88.22 89.47
Pivot Point 87.84 87.84 87.66 87.67 87.84
Support 1 (S1) 86.42 87.02 86.06 86.07 84.81
Support 2 (S2) 85.69 86.51 85.52 84.63
Support 3 (S3) 84.27 85.69 84.45
Support 4 (S4) 83.92